Mizuho's 9 Best Biotech Stocks to Buy for 2019
Biotech stocks are a staple among growth investors. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the risk is just as high. It's not unusual for these stocks to be cut in half or worse if drug-trial data disappoints or a drug application is rejected.
Thus, proper due diligence is critical, and that includes tapping the experts for information about these often difficult-to-gauge stocks.
Mizuho Securities has recently put out an analyst report highlighting its top biotechnology picks for 2019. And thanks to analyst ranking service TipRanks, we can see that the report's author, Managing Director Difei Yang, has a strong track record of stock recommendations. Yang is ranked in the top 250 out of more than 5,100 tracked analysts.
Yang writes, "We favor innovative and ground-breaking therapies in 2019; emerging technologies such as gene therapy and cell therapy could command substantial premiums from large cap pharma/biotech if impressive results are shown in historically difficult-to-treat conditions."
As Yang points out, pharma M&A is off to a strong start in 2019 with a number of blockbuster deals. They include Bristol-Myers Squibb's () $74 billion acquisition of Celgene (), and Eli Lilly's () $8 billion buyout of Loxo Oncology (). "In
